Traws Pharma Inc. (TRAW)
NASDAQ (CM) NASDAQ (CM) Primary 
Traws Pharma, Inc. (TRAW) Q2 2025 Earnings Call Transcript
Traws Pharma, Inc. (NASDAQ:TRAW ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Charles Parker - Interim Chief Financial Officer David Pauza - Corporate Participant Iain D. Dukes - Interim CEO, Secretary & Director Robert R.
Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript
Traws Pharma, Inc. (NASDAQ:TRAW ) Virtual Investor Event March 31, 2025 10:00 AM ET Company Participants Werner Cautreels – Chief Executive Officer Robert Redfield – Chief Medical Officer David Pauza – Chief Science Officer-Virology Iain Dukes – Executive Chairman Bruce Mackle – LifeSci Advisors Conference Call Participants Operator Good morning, and welcome to the Traws Pharma Investor Call on Bird Flu and COVID and Traws Innovative Small Molecule Product Candidates. At this time all attendees are in a listen-only mode.
Traws Pharma stock soars 200% on encouraging bird flu drug data
Shares of Traws Pharma Inc (NASDAQ: TRAW) more than tripled today after reporting encouraging early-stage data for its tivoxavir marboxil as a treatment of H5N1 bird flu. The investigational drug demonstrated safety and tolerability, and maintained blood levels above the EC90 for more than 23 days in a Phase I clinical trial.
Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript
Traws Pharma, Inc. (NASDAQ:TRAW ) Corporate Update Call August 15, 2024 8:00 AM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Werner Cautreels - CEO Mark Guerin - CFO Conference Call Participants Chong Liu - Ladenburg Thalmann Operator Operator Ladies and gentlemen, welcome to Traws Pharma, Inc. Corporate Update Call. At this time all participants are in a listen-only mode.
